CHA AI Healthkare Finalizes 5 Billion Won Convertible Bond Issuance: Potential 27% Dilution and Governance Risks Threaten Shareholder Value
CHA AI Healthkare finalized the issuance of its 33rd series unregistered unsecured private convertible bonds worth 5 billion won on June 18, 2026. Reduced from the initial 10 billion won, the bonds carry a 0% coupon rate and 1% maturity yield, with repayment at 103.0416% of principal at maturity in June 2029.
The conversion price is set at 12,463 won, a 91% premium over the current stock price of 6,530 won. However, a monthly reset clause allows the conversion price to drop to as low as 8,725 won in case of a market decline, potentially increasing dilution. Full conversion would add 401,267 shares, representing 2.20% of outstanding shares.
Including the existing 36th series CBs worth 40 billion won, total convertible shares reach 4,908,817, equivalent to 26.97% of current shares outstanding, posing significant dilution risk for existing shareholders.
The bonds are privately placed to CHACares, the largest contributor to the largest shareholder, raising governance concerns. The board resolution lacked participation from all two outside directors, highlighting weak oversight.
Proceeds of 5 billion won will be used entirely for investment purposes, but specific details are undisclosed, raising questions about capital allocation efficiency.
[AI Summary]CHA AI Healthkare's CB issuance features favorable terms for the issuer including low interest and a call option, but combined with existing CBs, potential dilution of 27% severely threatens shareholder value. The private placement to a related party and poor board attendance further undermine corporate governance credibility.
KOSPI Filing Information
[Correction of Description] Report on Major Matters (Decision on Issuance of Convertible Bonds)